(redirected from Urogenital Atrophy)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Category filter:
UGAUniversity of Georgia
UGAUndergraduate Admissions
UGAUniversity of Georgia College of Agricultural and Environmental Sciences
UGAUrban Growth Area
UGAUser Global Area (database)
UGAUnder General Anesthesia
UGAUser Global Area
UGAUniversal Graphics Array
UGAUlead Gif Animator
UGAUtah Golf Association
UGAUnited States Natural Gas Fund, LP (stock symbol)
UGAUtah Genealogical Association
UGAUncharted: Golden Abyss (gaming)
UGAUnited States Gasoline Fund LP (stock symbol)
UGAUndergraduate Advisor
UGAUnite de Gestion d'Alarme (French: Alarm Management Unit)
UGAUniversal Graphics Adapter (computer graphics standard)
UGAUnited Golf Association
UGAUrogenital Atrophy
UGAUser Group Administrator (computing)
UGAUndisclosed Government Agency (GPF comic)
UGAUkrainian Grain Association
UGAUser Group Alliance
UGAUniversal Game Adapter (gaming)
UGAUltra Graphics Array (1600 x 1200 pixels)
UGAUniversitari Gaudenti Associati
UGAUnited Graziers' Association of Queensland
UGAUnorganized Grab Ass
UGAUnited Gospel Artists
UGAUnité Géographique d'Analyse (French: Geographic Analysis Unit; pharmaceutical industry)
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The numerical scoring system allows for quantitative assessment of the progression (or regression with therapy) of urogenital atrophy. With "severe" atrophy, scores are usually [greater than or equal to] 8, whereas "moderate"atrophy scores are usually [less than or equal to] 6.
Urogenital atrophy usually occurs around the time of menopause, when the ovaries stop producing estrogen.
Benefits of HRT that are supported by strong scientific evidence include relief from menopausal symptoms such as hot flashes, prevention of osteoporosis, cardioprotective effects, relief of urogenital atrophy, and decreased urinary incontinence.
Vaginal atrophy (causing painful intercourse) and urogenital atrophy (ultimately contributing to incontinence) can also result from the loss of estrogen at the menopause.
Current evidence related to the role of three strategies is summarized below, including topical estrogen treatment of urogenital atrophy, vaginal moisturizers, and vaginal acidification.
The results of her research project, Exploring Symptoms Related to Urogenital Atrophy in Breast Cancer Survivors, have implications for improved cancer care and quality of life for breast cancer survivors.
Topical therapy for relief of urogenital atrophy symptoms may need to be continued long term.